Vanguard Group
ALBO

Vanguard Group’s Albireo Pharma Inc ALBO Stock Holding History

Vanguard Group’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-948,532
Closed -$20.5M – 4614
2022
Q4 		$20.5M Buy
948,532
+31,052
+3% +$656K ﹤0.01% 2617
2022
Q3 		$17.8M Sell
917,480
-76,490
-8% -$1.58M ﹤0.01% 2681
2022
Q2 		$19.7M Buy
993,970
+16,305
+2% +$430K ﹤0.01% 2649
2022
Q1 		$29.2M Buy
977,665
+42,235
+5% +$1.24M ﹤0.01% 2575
2021
Q4 		$21.8M Sell
935,430
-15,976
-2% -$425K ﹤0.01% 2793
2021
Q3 		$29.7M Buy
951,406
+27,009
+3% +$836K ﹤0.01% 2647
2021
Q2 		$32.5M Buy
924,397
+17,672
+2% +$575K ﹤0.01% 2589
2021
Q1 		$32M Buy
906,725
+20,925
+2% +$773K ﹤0.01% 2554
2020
Q4 		$33.2M Buy
885,800
+599,177
+209% +$21.8M ﹤0.01% 2400
2020
Q3 		$9.56M Buy
286,623
+36,572
+15% +$1.07M ﹤0.01% 2811
2020
Q2 		$6.62M Buy
250,051
+15,107
+6% +$356K ﹤0.01% 2965
2020
Q1 		$3.85M Buy
234,944
+21,007
+10% +$462K ﹤0.01% 3080
2019
Q4 		$5.44M Buy
213,937
+7,123
+3% +$142K ﹤0.01% 3143
2019
Q3 		$4.14M Buy
206,814
+29,167
+16% +$755K ﹤0.01% 3204
2019
Q2 		$5.73M Buy
177,647
+16,236
+10% +$543K ﹤0.01% 3120
2019
Q1 		$5.2M Buy
161,411
+4,179
+3% +$113K ﹤0.01% 3133
2018
Q4 		$3.86M Buy
157,232
+30,226
+24% +$799K ﹤0.01% 3167
2018
Q3 		$4.19M Buy
127,006
+1,109
+0.9% +$36.3K ﹤0.01% 3299
2018
Q2 		$4.47M Buy
125,897
+32,616
+35% +$1.06M ﹤0.01% 3247
2018
Q1 		$3.04M Buy
93,281
+62,262
+201% +$2.1M ﹤0.01% 3321
2017
Q4 		$794K Buy
31,019
+1,056
+4% +$26.8K ﹤0.01% 3661
2017
Q3 		$628K Sell
29,963
-506
-2% -$12.1K ﹤0.01% 3697
2017
Q2 		$628K Buy
30,469
+600
+2% +$12.3K ﹤0.01% 3684
2017
Q1 		$717K Buy
29,869
+1,404
+5% +$30.5K ﹤0.01% 3672
2016
Q4 		$505K Sell
28,465
-18,005
-39% -$374K ﹤0.01% 3734
2016
Q3 		$602K Sell
46,470
-4,496
-9% -$53K ﹤0.01% 3710
2016
Q2 		$475K Buy
50,966
+2,465
+5% +$27.2K ﹤0.01% 3808
2016
Q1 		$480K Buy
48,501
+11,341
+31% +$101K ﹤0.01% 3798
2015
Q4 		$382K Buy
37,160
+1,934
+5% +$20K ﹤0.01% 3894
2015
Q3 		$465K Buy
35,226
+11,955
+51% +$301K ﹤0.01% 3868
2015
Q2 		$720K Buy
23,271
+4,456
+24% +$150K ﹤0.01% 3756
2015
Q1 		$672K Buy
18,815
+1,438
+8% +$60.6K ﹤0.01% 3744
2014
Q4 		$693K Buy
17,377
+294
+2% +$12.9K ﹤0.01% 3639
2014
Q3 		$856K Buy
17,083
+608
+4% +$35K ﹤0.01% 3554
2014
Q2 		$1.07M Buy
16,475
+304
+2% +$21.1K ﹤0.01% 3467
2014
Q1 		$1.32M Buy
16,171
+2,112
+15% +$192K ﹤0.01% 3366
2013
Q4 		$970K Buy
14,059
+930
+7% +$68.1K ﹤0.01% 3425
2013
Q3 		$1.24M Buy
13,129
+352
+3% +$45.8K ﹤0.01% 3309
2013
Q2 		$1.6M Buy
+12,777
New +$1.33M ﹤0.01% 3145

Other funds holding ALBO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Vanguard Group's ALBO Position: Q1 2023 in Review

Vanguard Group sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 948,532 shares — an estimated $20.5M sold.

Vanguard Group first reported a position in ALBO in Q2 2013 and held it in 39 quarters. The position peaked at $33.2M in Q4 2020. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.

  • Vanguard Group reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
  • Vanguard Group sold 948,532 Albireo Pharma Inc shares in Q1 2023, an estimated $20.5M.
  • Vanguard Group first reported a position in Albireo Pharma Inc in Q2 2013 and held it in 39 quarters.
  • Vanguard Group's Albireo Pharma Inc position peaked at $33.2M in Q4 2020.
  • 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.

Based on Vanguard Group's 13F filing for Q1 2023, filed 15 May 2023.